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Abstract
Background: Duchenne muscular dystrophy (DMD) is an X-linked recessive disease that affects 1 in 3500–6000
male births. Despite broad research aiming to improve muscle function as well as heart and brain function, sufficient
therapeutic efficacy has not yet been achieved and current therapeutic management is still supportive. In a recent pilot
trial, oral treatment with L-arginine and metformin showed consistent changes of muscular metabolism both in vitro
and in vivo by raising NO levels and expression of mitochondrial proteins in the skeletal muscle tissue of patients with
DMD. This randomised, double-blind, placebo-controlled trial aims to demonstrate the superiority of L-citrulline
and metformin therapy over placebo in DMD patients with regard to the Motor Function Measure (MFM) D1
subscore (primary endpoint) as well as additional clinical and subclinical tests.
Methods/Design: A total of 40–50 ambulant patients with DMD will be recruited at the outpatient department
of the University of Basel Children’s Hospital (Switzerland), as well as from the DMD patient registries of Switzerland,
Germany and Austria. Patients will be randomly allocated to one of the two arms of the study and will receive either
a combination of L-citrulline and metformin or placebo for 26 weeks. Co-medication with glucocorticoids is allowed.
The primary endpoint is the change of the MFM D1 subscore from baseline to week 26 under L-citrulline and
metformin therapy. Secondary endpoints will include the motor function measure (MFM) and its items and subscores,
the 6-minute walking test, timed function tests and quantitative muscle testing. Furthermore, quantitative muscle MRI
assessment to evaluate the muscle fat fraction as well as safety and biomarker laboratory analyses from blood will be
included. For comparison, muscle metabolism and mitochondrial function will be analysed in 10–20 healthy
age-matched male children.
Discussion: The aim of this study is to test if a 6-month treatment of a combination of L-citrulline and metformin is
more effective than placebo in preventing loss of motor function and muscle degeneration in DMD. The MFM D1
subscore is used as a clinical outcome measure and a quantitative muscle MRI assessment as the surrogate
outcome measure of fatty muscle degeneration.
Trial registration: ClinicalTrials.gov: NCT01995032. Registered on 20 November 2013.
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Background
Duchenne muscular dystrophy (DMD) is characterized
by rapid and irreversible replacement of normal muscle
through connective and adipose tissue. The disease-
causing gene product, dystrophin, is present in many
different tissues throughout the body; however, the dis-
ease pathology is predominantly seen in skeletal and
heart muscle. Altered neuronal nitric oxide synthase
(nNOS), mitochondrial dysfunction and increased
intracellular calcium (Ca2+) concentrations have previ-
ously been described as impairing cellular function in
patients with DMD [1–7]. NO stimulates mitochondrial
biogenesis by increasing sirtuin 1 (SIRT1) and peroxi-
some proliferator-activated receptor-γ coactivator-1α
(PGC-1α) concentrations [8] and is also critical for
regulating muscle energy balance by activating AMP-
activated protein kinase (AMPK) [9]. NO and AMPK
may synergistically increase mitochondrial function and
biogenesis through independent mechanisms. There-
fore, impaired nNOS function likely contributes to the
observed mitochondrial dysfunction in DMD. Children
with DMD show an elevated synthesis of asymmetric
dimethylarginine (ADMA), a diminished homoarginine
(hArg) synthesis and a reduced NO bioavailability com-
pared to healthy children [10]. To increase NO levels to
stimulate mitochondrial function, reduce oxidative
stress and improve fat utilisation for energy production
appears to be a promising approach to ameliorate the
disturbed muscle cell metabolism in DMD. Activation
of nNOS in skeletal muscle is AMPK dependent [11],
and there is significant evidence for a beneficial effect
of AMPK activation in the mdx mouse model of DMD.
Chronic AMPK stimulation triggers beneficial adapta-
tions [12] and ameliorates the dystrophic phenotype in
the mdx mouse model [13]. One of the best-known
pharmacological AMPK activators elevating AMPK con-
centrations in human skeletal muscle is metformin [14].
Consistent with its described activation of AMPK, metfor-
min stimulates PGC-1α expression in the mdx mouse [15]
and protects skeletal muscle from degeneration [16]. In
summary, there is evidence that metformin in its role as
AMPK activator substitutes deficient nNOS function in
patients with DMD. This is achieved by direct stimulation
of nNOS and independent increase in PGC-1α expression,
both stimulating mitochondrial biogenesis.
To test the hypothesis of a synergistic effect of NO
and AMPK to stimulate mitochondrial function, we
conducted a proof-of-concept pilot trial in five patients
with DMD aged between 7 and 10 years [17]. That
study evaluated the subclinical and clinical benefits of a
combined therapy with the NO precursor L-arginine,
and the pharmacological AMPK activator and indirect
nNOS stimulator metformin over a treatment period of
16 weeks. The results of this trial were encouraging, as
the treatment in mostly steroid-naïve patients showed
increased NO formation in DMD muscle as expected.
More importantly, we also observed a positive correl-
ation between increased markers of NO concentration
and mitochondrial protein expression, indicating a direct
relation between intramuscular NO and mitochondrial
protein expression in DMD muscle. Motor function meas-
ure (MFM) scores and walking distances improved,
whereas ambulatory DMD patients older than 7 years
usually show a high annual decrease of MFM total and D1
subscores [18]. Despite the small number of patients, the
MFM total score (+3.6 %) and the D1 subscore (+6.2 %)
improved in comparison to published natural history data
and data for the standard treatment with steroids. Un-
treated ambulatory DMD patients older than 7 years
showed a median annual total MFM decrease of –7.9 %
(D1 subscore –17.2 %) [19]. Additional evidence for a
disease-slowing effect of the combination treatment was
provided by thigh muscle magnetic resonance imaging
(MRI) data, which did not show any significant increase of
the thigh muscle or body fat fractions during the time of
the study as expected, based on natural history data. This
pilot trial could confirm the theoretical concept of an
amelioration of muscular metabolism by stimulating mito-
chondrial function. However, the number of patients was
too small to generate significant clinical evidence for a
clear therapeutic effect. Thus, we will conduct a double-
blind, randomised, placebo-controlled efficacy and safety
study to prove efficacy of the treatment using clinical, la-
boratory and imaging outcome measures as endpoints.
Recently, it was shown that not only L-arginine, but
also L-citrulline, increases nitric oxide generation in
humans. Furthermore, the intake of L-citrulline leads to
higher peak concentrations of L-arginine than an
equivalent dose of L-arginine itself [20]. L-citrulline is a
precursor of L-arginine; three-fourths of L-citrulline are
converted to L-arginine in the kidney [21]. Single oral
doses up to 15 g have been well tolerated without side
effects [22]. Supplementation of L-citrulline restores
muscular L-arginine and reduces muscle wasting under
L-arginine-deficient and low-protein intake conditions
[23, 24]. Additionally, a direct protective effect of L-cit-
rulline on protein metabolism and skeletal muscle me-
diated through the inducible NOS (iNOS) isoform has
been suggested [25]. These considerations led us to




The study is an investigator-initiated, double-blind, ran-
domised, placebo-controlled efficacy and safety trial and
is conducted over a treatment period of 26 weeks. We
plan to enroll 40–50 ambulant patients with DMD aged
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between 6.5 and 10 years. Ethical approval has been ob-
tained from the local ethics committee (Ethics Commit-
tee of Both Basel cantons (EKBB EK63/13)) and the
National Swiss Drug Agency (Swissmedic). The trial was
registered at ClinicalTrials.gov (NCT01995032) prior to
starting recruitment. Patients and parents are being in-
formed about preclinical data, alternative treatments,
risks and possible benefits of the study. Oral informed
assent from affected children and written informed con-
sent from parents are being obtained. The participation
in this study is voluntary. If the patient or the parents do
not want to participate, they will not experience any dis-
advantages concerning further medical treatment. The
same applies if parents and patients withdraw their con-
sent at a later time. Patients or caregivers can withdraw
their consent or withdraw from the study without giving
any reason. In case of withdrawal, the data collected
until this point of time will be used, and the (blood)
samples collected in the context of the study will be
destroyed. In case of withdrawal, the patient will
undergo a final visit for medical examination for his own
safety. To obtain normal values for measures of muscle
metabolism and mitochondrial function, blood and urine
samples are analysed in 10–20 healthy age-matched
male children. Data is collected at the University Chil-
dren’s Hospital in Basel, Switzerland.
Inclusion criteria
Inclusion criteria are molecular diagnosis of DMD; 6.5–
10 years of age at time of screening; ambulant patients
with ability to walk 150 m in the 6-minute walking test
(6MWT); D1 subdomain of the MFM scale >40 %; stable
treatment with steroids for >6 months or steroid-naïve
patients.
Exclusion criteria
Excluded are patients with a previous (within the past
3 months) or concomitant participation in any other
therapeutic trial; the use of L-citrulline, L-arginine or
metformin within the last 3 months; a known individual
hypersensitivity to L-citrulline or metformin; a known or
suspected malignancy; any other chronic disease or clin-
ical relevant limitation of renal, liver or heart function
according to the discretion of the investigator; or the
start of glucocorticoid treatment or change in dosage
<6 months prior to screening.
Randomisation and blinding
Patients that meet the study admission criteria are en-
rolled in the study and are assigned a single subject
identification number. Patients are subsequently allo-
cated to the two study groups, L-citrulline and metfor-
min or placebo, according to a mixed randomisation
scheme with an unbalanced starting block of 5 patients
and subsequent randomly permuted balanced blocks of
2 or 4 patients [26]. The trial is double-blind, with both
participants/parents as well as investigators assessing
outcomes blinded to treatment allocation. The patients
randomised to the placebo group receive a matching pla-
cebo with sachets and powder as well as capsules look-
ing like verum but not containing active ingredients.
Drop-outs after the baseline visit are not replaced.
Intervention
All patients randomised to the active compounds receive
L-citrulline (Hospital pharmacy, Basel, Switzerland)
2.5 g/d t.i.d. as well as metformin (metformin hydro-
chloride, Hospital pharmacy, Basel, Switzerland) at a
dose of 250 mg t.i.d. Patients allocated to the placebo
group receive matching placebo (mannitol) with sachets
and powder as well as capsules looking like verum
(L-citrulline sachets and metformin capsules). Treatment
is given for a period of 26 weeks. Co-medication with
glucocorticoids (standard treatment) is allowed and con-
tinued if treatment was started >6 months before random-
isation. At baseline as well as at the end of the study,
clinical measures, laboratory and MRI measures are
performed. This includes the MFM scale, 6MWT, MFC
assessment using quantitative thigh muscle MRI and la-
boratory blood analysis (Fig. 1).
Study procedure
At screening (visit 1, day –1), patients and parents are
informed about preclinical data, alternative treatments,
risks and possible benefits of the study. Further, oral in-
formed assent from affected children and written in-
formed consent from parents are obtained. After
signing the informed consent form, the inclusion and
exclusion criteria are verified. If the criteria are fulfilled,
the patient will be enrolled in the study. During this
screening visit the following procedures are performed:
vital signs, physical examination, MFM scale, 6MWT,
muscle force of knee extension and elbow flexion using
hand-held dynamometry and 10 m within 10 s walking
test. After screening, visits will be scheduled for 0 (visit
2, baseline), 13 (visit 3) and 26 (visit 4, end of study)
weeks.
During visit 2 (week 0, baseline) the following proce-
dures are performed: check inclusion/exclusion criteria,
adverse events and vital signs, physical examination,
blood draw (laboratory analysis) and muscle MRI. If the
patient still qualifies for the study, he will be rando-
mised and receive the corresponding study medication.
During visit 3 (week 13) the following procedures are
performed: check for adverse events, dispensing of
study medication, collection of bottles and boxes with
sachets of used study medication for compliance con-
trol, check vital signs, physical examination, blood draw
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Fig. 1 Flow chart showing the study design
Table 1 Patient timelines / scheme of interventions
Visit 1 2 3 4








Dispensing of study medication X X
Collection of study medication X X
Metformin serum concentration (compliance check) X
Assessments:
Medical history and demographics X
Capture Adverse Events X X X
Vital Signs (blood pressure, heart rate, weight, height X X X X
Physical examination (general and neurological) X X X X
Blood and urine analysis: amino acids, haematologyb, chemistryc, markers of oxidative stress
and NO function
X X X
MFM scale Xa X X
Muscle force of knee extension and elbow flexion using hand held dynamometry Xa X X
6MWT Xa X X
Timed function test: 10 m walking test, Supine up Xa X X
MRI X X
aWill be used as baseline values
bFull blood count: erythrocytes, reticulocytes, leucocytes, platelets, haemoglobin, haematocrit
cLiver and renal function tests, electrolytes, urea, creatine kinase, HbA1c, cholesterol, high and low density lipoprotein (HDL, LDL) triglycerides
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(laboratory analysis), MFM scale, 6MWT, muscle force
of knee extension and elbow flexion using hand-held
dynamometry and a 10 m within 10 s walking test.
During the last visit (visit 4, week 26, end of study) the
following procedures are performed: check for adverse
events, collection of study medication, check vital signs,
physical examination, blood draw (laboratory analysis),
MFM scale, 6MWT, muscle force of knee extension and
elbow flexion using hand-held dynamometry, 10 m
within 10 s walking test and muscle MRI (Table 1).
Healthy controls
Between 10 and 20 healthy age-matched boys are enrolled
to obtain normal values of mitochondrial and muscle me-
tabolism. Healthy children and their caregivers are asked
to participate in our study while undergoing an elective
surgery at our hospital. Blood is collected as part of the
routine safety protocol while the child is under anaesthe-
sia. An additional amount of 4 ml of blood is drawn, but
no additional venous puncture is necessary for this study.
At screening (visit 1, day –1) patients and parents are in-
formed about the procedure. Oral informed assent from
the children and written informed consent from parents
are obtained. If the inclusion criteria are fulfilled and no
exclusion criteria are met, the patient will be enrolled in
the study. During the baseline visit the inclusion and ex-
clusion criteria are checked and a urine sample is taken.
Blood collection is performed the same day, as explained
above.
Inclusion criteria healthy volunteers
The inclusion criteria are male sex and aged between 6.5
and 10 years.
Exclusion criteria healthy volunteers
The exclusion criteria are previous (within the past
3 months) or concomitant participation in any other
therapeutic trial, use of L-citrulline, L-arginine or metfor-
min within the last 3 months, known genetic or acquired
neuromuscular disorder, known or suspected malignancy
and other chronic disease or clinical relevant limitation
of renal, liver or heart function according to the discre-
tion of the investigator.
Quality assurance
To assess high-quality conduct of the trial in accordance
with the protocol, all medical staff involved in this study
are certified in good clinical practice (GCP). Moreover,
physiotherapists are certified to perform the motor func-
tion measures. To assess compliance of medication in-
take, empty and full bottles and boxes with sachets are
returned by the patients at visits 3 and 4.
Safety assessments
Adverse events are monitored throughout the study. At
every study visit patients and caregivers are asked about
adverse events, a clinical examination is performed and
the vital parameters are measured. The following safety
parameters amongst other parameters are checked: a full
blood count and clinical chemistry (transaminases, cre-
atinine, electrolytes, urea) will be measured as well as
creatine kinase concentration as a marker of muscle ne-
crosis. The intake of metformin will be stopped in case
of an increase of creatinine and transaminases >2 ×
upper limit of baseline. Withdrawal of consent, protocol
violations caused by the patients (noncompliance), logis-
tical reasons, inability to attend study visits as defined in
the protocol or abnormal laboratory results, including
liver or renal function tests and abnormal increase in
blood pressure as determined by the investigator can
lead to an early termination of the study.
Patients with adverse reactions which have occurred
during the study are followed up by the investigator up
to 30 days after the last visit.
If pathologic changes independent of the known
muscle disease are detected, the affected patients will be
informed immediately, and the need for further diagno-
sis and treatment according to current medical know-
ledge will be discussed.
Outcome measures
Primary outcome measure
Change of MFM D1 subscore from baseline to week
26 under L-citrulline and metformin therapy Several
tests have been reported in the literature to assess
muscle strength and functional ability, to monitor the
progression of the disease and to evaluate the results of
drug interventions and rehabilitation. However, most in-
struments can assess ambulant patients only, making ad-
justments and/or additional assessments necessary when
the disease progresses. The MFM, a validated assessment
tool to measure motor function in both ambulant and
non-ambulant patients with neuromuscular disorders,
was developed in 2005 in France. It includes 32 items
that evaluate three dimensions of motor performance,
including specific motor functions, such as transfers and
standing posture (D1), proximal and axial (D2), distal
(D3) and a total MFM score involving all of the motor
dimensions. The items are scored and summarised to
comprise a total score, in which the maximum score
represents normal motor function. The instruction man-
ual, validation examinations and other publications using
the MFM can be downloaded at the MFM website
(http://www.motor-function-measure.org/home.aspx). In
a recent study, the annual decrease of the total score
was 5.8 % for patients with DMD, indicating an overall
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decline in motor capacities [27]. However, independent
examination of the D1, D2 and D3 subscores provided
more information depending on the stage of the disease.
In ambulant DMD patients, D1 was the most inform-
ative score, with a mean decrease of 17.2 % per year be-
fore loss of ambulation in patients aged 6 years and
older. D1 seems to us to be particularly interesting be-
cause it is related to loss of ambulation and is responsive
to short-term changes (3 months) and should provide
sufficient information in a 6-month trial. Consistent with
this, in our previous 16-week L-arginine and metformin
pilot trial in ambulant patients with DMD, the D1 sub-
score provided the best effect size of all evaluated clin-
ical parameters [17].
Secondary outcome measures
Change of MFM total score, the D2 and D3 MFM
subscores from baseline to week 26 under L-citrul-
line/metformin therapy According to Bushby et al.
[27], D2 is the most informative subscore after loss of
ambulation, with an average decrease of 9.4 % per year.
In patients older than 14 years, the average decrease in
D3 was 10.8 % per year [27].
Change of walking distance assessed with the 6-
minute walking test Timed clinical function tests, like
the 6-minute walking test (6MWT), are helpful in asses-
sing muscle function in children with DMD. The
6MWT has been validated for use in DMD trials and
measures the distance an individual is able to walk over
a total of 6 minutes on a hard, flat surface. The goal for
the person is to walk as far as possible in 6 minutes. The
individual is allowed to self-pace and rest as needed as
they traverse back and forth along a marked walkway.
Data from 112 DMD patients aged 4–17 years in an
Italian cohort showed that the 6MWT performances
increased (approximately 33 m/year) with age up to
7 years, with a clear point of slope change at approxi-
mately 7 years. After the age of 7 years, there was a
variable decline in the 6MWT (–12 m/year) [28].
Change of quantitative muscle MRI including muscle
fat fraction and T2 times of thigh muscles visualised
by MRI In muscular dystrophies quantitative muscle
MRI (qMRI) detects disease progression more sensitively
compared to other clinical scores. Excellent reproduci-
bility of qMRI was demonstrated in healthy volunteers
as well as in patients [29, 30]. The qMRI test was more
sensitive than clinical evaluation and visual analysis of
MRI scans to detect disease progression [31, 32]. As re-
cently investigated in 20 DMD patients, muscle fat frac-
tion (MFF) in patients with DMD shows excellent
correlation to clinical parameters, but is less variable
and is therefore useful as a surrogate outcome parameter
in patients with DMD [33]. Sample size estimations for
qMRI data are up to 17 times smaller compared to the
MFM total score and up to 7 times smaller compared to
the D1 subscore, respectively.
Change in plasma and urine laboratory parameters
Aims of our treatment are: (1) an elevation of NO con-
centrations measured by indirect markers such as nitro-
tyrosine, nitrate, nitrite, asymmetric dimethylarginine
(ADMA)); (2) an improvement of muscular energy state
with reduction of oxidative stress measurable by 8-
hydroxydeoxyguanosine (8OHDG) in urine and carbony-
lated protein concentration in the serum; (3) a slowing
of muscle degeneration measured by creatine kinase,
transaminases and alkaline phosphatase levels in serum.
Normal values for markers of oxidative and nitrosa-
tive stress and miRNA in serum and urine Normal
values of indirect markers of NO concentrations as well
as oxidative stress will be measured in a healthy cohort
of 10–20 male children aged 6.5 to 10 years.
Change of quantitative muscle testing of knee exten-
sion and elbow flexion using hand-held dynamometry
To measure muscle force independent of muscle func-
tion and aspect, quantitative muscle testing (QMT) of
knee extension and elbow flexion will be done using a
dynamometer [34].
Randomisation scheme
Since a complete blinding of the physicians involved in
the trial cannot be guaranteed, a mixed randomisation
scheme is used following the recommendation of Schulz
and Grimes [26]. An unequal starting block of size 5 is
generated using replacement randomisation. Then ran-
domly permuted blocks with equal numbers of assign-
ments to the two groups (verum and placebo) are
appended. Block sizes are 2 or 4 and are selected ran-
domly with equal probability. For emergency breaking of
the group assignment, unblinding envelopes are pro-
vided. These envelopes have a window in which only the
running patient's ID is visible and contain an unblinding
form that states the patient's group assignment.
Sample size estimation
Sample size estimation was based on the primary end-
point MFM D1 subscore. A semi-parametric approach
was chosen that made use of our own data from a com-
parable pilot trial [17]. Each sample size, ni = 1,…,40 = 11,
…, 50, was evaluated by drawing 99 times an individual
data set of size ni from the pilot study data set (sampling
with replacement). In each of these individual data sets,
each patient was randomly assigned to the verum or a
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placebo group. For each patient, the post-treatment
value was calculated as the sum of the baseline value
and a random variate drawn from a normal distribution.
Its standard deviation was estimated from the pilot data.
For the placebo group, the mean change from baseline was
set to –17.2/52 × 16 =–5.3 (value taken from Table 2 in
[27]). (The value from [27] refers to changes within one
year, i.e. approximately 52 weeks, and the pilot study lasted
16 weeks, thus the linear transformation of the values by
/52 × 16.) For the verum group, the mean change from
baseline was varied from 1 to 10 (in the pilot data, the
mean change from baseline was 6.1). The resulting data set
was analysed with an ANCOVA model (as outlined in the
next section). The proportion of repetitions with a signifi-
cant outcome corresponds to the estimated power. Assum-
ing a drop-out rate of 10 %, a significance level of 0.05 and
a power of 0.8, 47 patients should be recruited in order to
be able to analyse 42 complete data sets. Figure 2 shows
how the sample size behaves with regard to the MFM D1
subscore and the power.
Statistical analyses
The hypothesis is that patients in the verum group will
have a larger MFM D1 subscore than patients in the pla-
cebo arm after 13 or 26 weeks. If assumptions are not vi-
olated, ANCOVA models are used for the primary
analysis. The response variable is the D1 subscore after
13 or 26 weeks; i.e. separate models for the 13 and
26 weeks follow-up measurements are formulated. The
explanatory variables are D1 at baseline and trial group.
The model estimates are presented together with 95 %
confidence intervals and p values with respect to the null
hypothesis that the corresponding coefficient is zero. In
addition to the unadjusted analysis, an analysis adjusted
by the binary variable indicating whether the patients
were under cortisol treatment is conducted. The ana-
lyses are done following the intention-to-treat (ITT)
principle. If assumptions of ANCOVA are violated, non-
parametric ANCOVAs are used instead (Bowman and
Azzalini [35]).
The analyses are repeated based on the per protocol
(PP) principle. Deviations from the results of the ITT
analysis are described in detail. Furthermore, the ITT
analyses are repeated on an imputed data set where
missing measurements at week 13 or 26 are set accord-
ing to the last-observation-carried-forward (LOCF)
principle. Deviations from the results of the non-
imputed ITT analysis are described in detail. One sub-
group analysis is performed based on patients’ baseline
measurement of 6-minute walking distance, where sub-
groups are defined as walking distance >350 m or
<350 m. The same procedure as used for the analysis of
the primary endpoint is employed for the analysis of
each subgroup. With the aim of generating hypotheses,
the above procedure for the primary endpoint is applied
to all secondary endpoints.
Quality control
To assure the quality of the study conduct and of the
data, monitoring of the study is performed by organisa-
tions independent of the study (Clinical Trial Unit,
University Hospital Basel, Kammermann Monitoring
Services GmbH). All inclusion and exclusion criteria
are checked, and the monitor controls if the data have
Fig. 2 Sample size estimation. Sample size with regard to the MFM D1 subscore and the power for a randomisation ratio of 1:1. The numbers on
the curves indicate the power. The arrows show how to interpret the plot. The curves are smoothed and only serve illustrative purposes
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been recorded correctly in the case report form, if the
drug accountability is correct and if serious adverse
events have occurred during the study. A Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) checklist (Additional file 1) is added to
the publication of the protocol.
Discussion
We propose a single-centre, randomised, double-blind,
placebo-controlled trial to determine whether treatment
with L-citrulline and metformin has a positive effect on
clinical function and paraclinical surrogate biomarkers
in Duchenne muscular dystrophy (DMD). If the com-
bined treatment of L-citrulline and metformin is proven
to be effective, it will offer a new symptomatic treatment
option to slow muscular decline and therefore extend
the time of free ambulation.
Planning clinical trials in DMD is challenging for the
following reasons. (1) Disease progression does not follow
a linear course when physical abilities are measured. Lon-
gitudinal studies using clinical measurements showed an
improvement of gross and fine motor function up to the
age of 6 to 7 years, then a plateau phase up to the age of
10 and then a phase of rapid decline during which free
ambulation is lost [18, 28]. (2) DMD is a rare disease,
making recruitment for clinical trials difficult. (3) Clinical
assessment is dependent on cooperation and often differs
between ambulant and non-ambulant patients [33]. Sev-
eral motor function or timed motor performance tests are
validated to assess disease progression in DMD, such as
the Northstar Ambulatory Assessment (NSAA) [28], the
6-minute walking distance [36] and the Hammersmith
Functional Motor Scale [37]. The Motor Function Meas-
ure (MFM) is a validated clinical score recommended in
the guidelines on the clinical investigation of medicinal
products for the treatment of DMD published by the
European Medicines Agency [38]. Its interrater variabil-
ity is low [18]. It was shown to be highly correlated to
age in patients with DMD and was even to some extent
predictive for loss of ambulation in these patients. Loss
of ambulation was shown to occur about one year after
the MFM total score dropped below 70 %, or a drop in
D1 subscore below 40 %, respectively [18]. A main ad-
vantage of the MFM over other commonly used motor
function or timed motor performance tests is that it
can be used continuously throughout the course of a
disease regardless of the severity of the disease and the
patient’s ambulatory status [38].
Recently, we demonstrated that out of all analysed clin-
ical measures, the MFM D1 subscore showed the most
significant decline in ambulant DMD patients >7 years,
resulting in the highest effect size and the lowest required
patient numbers to treat [33]. This score also seems to be
particularly interesting because of its relation to loss of
ambulation and its responsiveness to short-term changes.
Therefore, to test our approach we selected the MFM D1
as the (primary) endpoint for the selected population of
ambulant patients with DMD. For sample size estimation
using the MFM D1 subscore as primary endpoint and as-
suming a drop-out rate of 10 %, a randomisation ratio of
1:1 and a power of 0.8, 42 patients should be recruited in
order to be able to analyse 38 complete data sets. To be
able to recruit sufficient patients in a reasonable time we
choose to include patients with a walking distance of more
than 150 m in 6 minutes. This is not optimal and is likely
to include patients in a stable as well as a more unstable
phase. Therefore, predefined subgroup analysis of patients
walking more (stable group) or less (unstable group) than
350 m in the 6MWT has been planned.
To further increase the sensitivity to detect whether
our intervention has a beneficial effect on muscle degen-
eration, we will use thigh muscle qMRI as a surrogate
biomarker as the most important secondary endpoint. A
surrogate (imaging) outcome measure must provide evi-
dence of whether the treatment provides a clinically
meaningful benefit. Therefore, it must (1) correlate with
the clinical endpoint, (2) be sensitive to the effects of the
intervention, (3) be clinically relevant to the disease and
the treatment and (4) be readily measurable and inter-
pretable [39]. The qMRI fulfils all these conditions, if
protocols for qMRI are set up in advance with regard to
patient positioning, slice selection and ROI delineation,
and if the technical staff performing the examination
and evaluation have been trained accordingly. Recently
we demonstrated that in comparison to clinical end-
points the effect sizes of qMRI were much larger in
DMD patients; e.g. sample size estimations for qMRI
data were up to 17 times smaller compared to the MFM
total score and up to 7 times for the D1 subscore, re-
spectively [33]. Thus, in case our sample size estimation
(using the clinical endpoint) was inaccurately low, qMRI
should still be able to detect whether our intervention
can affect disease progression positively.
The determination of normal values of markers of
muscle metabolism and mitochondrial function in blood
and urine in an age-matched healthy cohort will allow a
better integration of an eventual stimulation of NO con-
centration and reduction of oxidative stress in treated
patients with DMD.
Trial status
The trial started enrolment in January 2014 and is ex-
pected to be completed by the end of May 2016.
Additional file
Additional file 1: SPIRIT checklist. (PDF 60.4 kb)
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